scispace - formally typeset
D

Douglas S. Johnson

Researcher at Pfizer

Publications -  90
Citations -  4695

Douglas S. Johnson is an academic researcher from Pfizer. The author has contributed to research in topics: Fatty acid amide hydrolase & DNA Alkylation. The author has an hindex of 33, co-authored 90 publications receiving 4214 citations. Previous affiliations of Douglas S. Johnson include Scripps Research Institute.

Papers
More filters
Journal ArticleDOI

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

TL;DR: Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile, and designate PF- 3845 as a valuable pharmacological tool for in vivo characterization of the endocannabinoid system.
Journal ArticleDOI

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

TL;DR: This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.
Journal ArticleDOI

Cc-1065 and the duocarmycins : understanding their biological function through mechanistic studies

TL;DR: In this article, the authors define the DNA alkylation properties of a class of potent antitumor antibiotics that includes CC-1065 and duocarmycins, as well as investigations that delineate fundamental relationships between their structure, functional reactivity, and biological properties.
Journal ArticleDOI

CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

TL;DR: Key studies defining the DNA alkylation properties and selectivity of a new class of exceptionally potent, naturally occurring antitumor antibiotics including CC-1065, duoc Carmycin A, and duocarmycin SA are reviewed.
Journal ArticleDOI

Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity

TL;DR: The piperidine/piperazine urea may represent a privileged chemical scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.